We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.59B
AUM Growth
-$301M
(-6.2%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-9.37%
Top 10 Holdings %
Top 10 Hldgs %
42.8%
Holding
130
New
21
Increased
24
Reduced
35
Closed
20
Top Buys
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pfizer
PFE
$140B
| $54.7M | 1.19% |
1,946,500
+293,600
| +18% | +$7.82M |
|
27
Dyne Therapeutics
DYN
$3.91B
| $52.9M | 1.15% |
2,917,884
+715,700
| +32% | +$12.3M |
|
28
Natera
NTRA
$39.5B
| $52.4M | 1.14% |
262,000
-103,800
| -28% | -$22.3M |
|
|
ABVX
29
Abivax
ABVX
$11.9B
| $51.9M | 1.13% |
465,700
+97,800
| +27% | +$11.6M |
|
|
UPB
30
Upstream Bio Inc
UPB
$393M
| $51.2M | 1.12% |
5,693,589
| – | – |
|
31
Danaher
DHR
$142B
| $50.4M | 1.1% |
265,800
-34,000
| -11% | -$7.24M |
|
|
CAI
32
Caris Life Sciences
CAI
$4.86B
| $50.2M | 1.09% |
2,806,811
-309,200
| -10% | -$6.76M |
|
33
Avita Medical
RCEL
$131M
| $42.5M | 0.93% |
+544,895
| New | +$2.29M |
|
34
Ascendis Pharma A/S
ASND
$17.4B
| $41.6M | 0.91% |
181,977
+10,000
| +6% | +$2.24M |
|
35
Shattuck Labs
STTK
$620M
| $40.5M | 0.88% |
6,306,127
| – | – |
|
|
36
Guardant Health
GH
$21.6B
| $40.2M | 0.88% |
+435,200
| New | +$43.7M |
|
|
37
Alnylam Pharmaceuticals
ALNY
$37.6B
| $39.4M | 0.86% |
119,000
-169,800
| -59% | -$57.8M |
|
38
Prelude Therapeutics
PRLD
$348M
| $37.3M | 0.81% |
10,909,256
| – | – |
|
39
Crinetics Pharmaceuticals
CRNX
$8.89B
| $36.3M | 0.79% |
999,000
| – | – |
|
40
Axsome Therapeutics
AXSM
$11.9B
| $36.2M | 0.79% |
213,921
-39,200
| -15% | -$6.77M |
|
|
41
uniQure
QURE
$2.8B
| $34.9M | 0.76% |
2,136,149
+1,398,749
| +190% | +$28.3M |
|
42
Oric Pharmaceuticals
ORIC
$1.13B
| $34.1M | 0.74% |
2,693,929
-947,827
| -26% | -$10.8M |
|
43
Elevance Health
ELV
$83.5B
| $33.6M | 0.73% |
114,700
+15,600
| +16% | +$5.13M |
|
44
Relmada Therapeutics
RLMD
$653M
| $32.8M | 0.72% |
4,715,864
+2,105,264
| +81% | +$9.96M |
|
45
Forte Biosciences
FBRX
$937M
| $31M | 0.68% |
1,196,955
| – | – |
|
46
Trevi Therapeutics
TRVI
$2.48B
| $29.3M | 0.64% |
2,454,400
-736,300
| -23% | -$8.24M |
|
47
Esperion Therapeutics
ESPR
| $29M | 0.63% |
10,570,300
+4,604,802
| +77% | +$14.6M |
|
48
Neuropace
NPCE
$548M
| $27.6M | 0.6% |
2,096,527
-309,808
| -13% | -$4.65M |
|
49
Rhythm Pharmaceuticals
RYTM
$7.43B
| $27.3M | 0.6% |
314,100
+74,300
| +31% | +$7.23M |
|
50
Thermo Fisher Scientific
TMO
$199B
| $22.9M | 0.5% |
46,500
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM